Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Teclistamab-Daratumumab in AL Amyloidosis — Stella

Home/Amyloid Light-chain Amyloidosis/Teclistamab-Daratumumab in AL Amyloidosis

View on ClinicalTrials.gov

Recruiting

Back to Amyloid Light-chain Amyloidosis trials

Teclistamab-Daratumumab in AL Amyloidosis

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

United States

Columbia University Irving Medical Center, New York, New York

Key details

Phase

Safety & dosing

Sponsor

Suzanne Lentzsch, MD

Collaborators

Janssen Pharmaceuticals

Enrollment target

~25 participants

Started

November 2025

Primary completion

October 2031

Age range

18 Years – 100 Years

Last updated November 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.